Medicine
Crysvita 20 mg/1 mL injection
Crysvita 20 mg/1 mL injection is a prescription medicine containing Burosumab for subcutaneous use, marketed by Kyowa Kirin, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
CRYSVITA vials must be stored in the original carton until the time of use…
Key facts
- Active ingredient (INN)
- Burosumab
- Brand
- Crysvita
- Strength
- 20 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 vial of 1 mL
- Marketing authorisation holder
- Kyowa Kirin
- Manufacturer
- Kyowa Kirin
- Origin register
- US FDA, United States
- Storage
- CRYSVITA vials must be stored in the original carton until the time of use under refrigerated conditions at 36°F to 46°F (2°C to 8°C). Do not freeze or shake CRYSVITA. Keep CRYSVITA vial in the original carton to protect from light until time of use.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- M05BX05 Burosumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 April 2018
- Identifiers
- RxCUI 2043859, 2043864, 2043868 +3DailyMed set ID 102f96a0-6e3a-4fc1-b204-34d604683af6NDC 42747-203Application BLA761068
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 1 mL in 1 vial, single-use | 42747-203-01 | Kyowa Kirin | 1 September 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Burosumab
Clinical summary
Burosumab is a prescription medicine indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Burosumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BurosumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- CRYSVITA prescribing information (Kyowa Kirin) · U.S. National Library of Medicine, DailyMed
- Crysvita: European public assessment report (EPAR) · European Medicines Agency
Need Crysvita 20 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.